Close



Mar 14, 2024 06:50AM
Mar 7, 2024 06:50AM
Feb 23, 2024 06:50AM
Dec 26, 2023 06:50AM
Dec 26, 2023 06:50AM
Nov 6, 2023 06:50AM
Oct 30, 2023 06:50AM Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023
Oct 9, 2023 06:50AM
Oct 9, 2023 06:50AM
Sep 12, 2023 06:50AM
Sep 6, 2023 06:50AM
Aug 7, 2023 06:50AM
Aug 1, 2023 06:50AM
Jul 31, 2023 06:50AM Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023
Jun 8, 2023 06:50AM
May 30, 2023 06:52AM
May 30, 2023 06:50AM
May 23, 2023 06:52AM
May 23, 2023 06:50AM
May 18, 2023 06:59AM
May 18, 2023 06:50AM Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases
May 10, 2023 06:01AM
May 10, 2023 06:00AM
May 5, 2023 06:47AM
May 5, 2023 06:46AM
May 4, 2023 06:50AM
Apr 27, 2023 06:50AM
Mar 21, 2023 06:50AM Protalix BioTherapeutics (PLX) Doses First Patient in Human Phase I Trial of PRX-115
Mar 21, 2023 06:50AM
Mar 13, 2023 06:53AM
Mar 13, 2023 06:50AM
Feb 27, 2023 06:30AM
Feb 24, 2023 09:16AM
Feb 24, 2023 09:15AM
Feb 21, 2023 06:55AM Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023
Feb 21, 2023 06:50AM
Jan 3, 2023 06:52AM
Jan 3, 2023 06:50AM
Dec 21, 2022 04:31PM
Dec 21, 2022 04:30PM
Dec 5, 2022 06:53AM
Dec 5, 2022 06:50AM Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed
Dec 4, 2022 09:00AM
Nov 14, 2022 06:50AM
Nov 14, 2022 06:31AM
Nov 14, 2022 06:30AM
Nov 7, 2022 06:50AM
Sep 12, 2022 12:40PM
Sep 6, 2022 06:50AM Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 15, 2022 06:50AM

251,891 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All